Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Psychedelics represent one of the most promising classes of experimental medicines for the
treatment of neuropsychiatric disorders due to their ability to promote neural plasticity and …

Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the
acute experience mediates long-term improvements in mental health. In the present paper …

Objective: Subanesthetic ketamine doses have been shown to have rapid yet transient
antidepressant effects in patients with treatment-resistant depression, which may be …

Psychedelic drugs are making waves as modern trials support their therapeutic potential
and various media continue to pique public interest. In this opinion piece, we draw attention …

Objective: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces
opioid system activation. The objective of this study was to determine whether opioid …

Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike
any treatments currently available. Not only do they produce sustained therapeutic effects …

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA
receptor antagonist, to induce rapid (within hours), transient antidepressant effects when …

Ketamine produces immediate antidepressant effects and has inspired research into next-
generation treatments. Ketamine also has short term dissociative effects, in which …